Ratiopharm in Sweden: Exploiting Electronics
Increasingly competitive generics markets are forcing companies to be as creative as they can in securing even a few weeks' head-start over competitors. Ratiopharm is exploiting Swedish GPs' widespread use of electronic prescription systems to circumnavigate a timing quirk in the country's substitution law and gain vital market share for its generic omeprazole.
You may also be interested in...
Germany's Schwarz has invested heavily in its transition from a marketing organization into a development-based firm. Higher-than expected windfall revenues from generic omeprazole increase its chances of a successful transformation.
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda?